Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Coronavirus Disease 2019: early-phase trial registry
1 of 5 indexed Coronavirus Disease 2019 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Coronavirus Disease 2019: 5 US clinical trials tracked, 1 recruiting.
Coronavirus Disease 2019 is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is CytoDyn, running 2 of these trials.
Enrollment posture brief
Registry condition coronavirus-disease-2019
OPEN 1 | RECR 20% | LATE 0 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Coronavirus Disease 2019 lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Coronavirus Disease 2019 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Coronavirus Disease 2019 is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Coronavirus Disease 2019 research.
CytoDyn accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Coronavirus Disease 2019 enrolment sits around 240 participants.
Median target enrolment is 240 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Coronavirus Disease 2019 research leans observational.
2 interventional and 3 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
Weill Medical College of Cornell University
NCT05164744
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
Pfizer
NCT05160636
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04401436
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
CytoDyn
NCT04343651
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
CytoDyn
NCT04678830
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Named interventions
Most-linked intervention names on Coronavirus Disease 2019 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Coronavirus Disease 2019 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Coronavirus Disease 2019 page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Coronavirus Disease 2019 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- CytoDyn sponsors the most Coronavirus Disease 2019 trials on record, review their full trial history before evaluating a specific study. See CytoDyn's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronavirus Disease 2019 condition card totals 5 registered trials; most-linked intervention Leronlimab (700mg); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.